ASTRA RHINOCORT FOR ALLERGIC RHINITIS SLATED FOR FALL LAUNCH
Executive Summary
ASTRA RHINOCORT FOR ALLERGIC RHINITIS SLATED FOR FALL LAUNCH following the budesonide nasal inhaler's approval Feb. 14. The drug will be marketed by Astra USA's Rx Division and will be introduced in time for the autumn allergy season, the company said. Astra filed NDA 20-233 for Rhinocort on Dec. 20, 1991. FDA classified the corticosteroid as a "1S" drug, designating a new molecular entity receiving standard review.